From Research Influencers to Substance Use Policymakers: Bibliometrics Demonstrate Translation from Research to Policy

The public health impact of substance use (SU) is substantial, with tobacco use and excessive drinking leading as causes of death in the USA. To address this growing epidemic, governments have implemented a range of SU-related policies. The NIH’s Clinical & Translational Science Awards (CTSA) program, which aims to accelerate translation of research findings into health impact, may advance translation through its impact on the policy literature that informs policymakers, health professionals, and the public. Using innovative bibliometric tools, this study evaluates how CTSA-supported research published from 2006-2023 has influenced SU-related policy literature.

The authors identified 135K publications that acknowledged CTSA support. Those publications were queried in the Overton Policy database, which indexes references to research publications in global policy literature.

Thus far, CTSA-supported publications have been cited in 3,451 policy documents identified as SU-related according to Overton’s Topics field. SU-related Topics were classified into top categories of: Tobacco, Opioids, Cannabis, Alcohol, and General/Other SU. Policy documents came from 321 organizations across 49 countries- often governments, health agencies, or political think tanks, including the World Health Organization, Guidelines in Pubmed Central, and the RAND Corporation. The authors present case illustrations of individual research publications that have had notable influence on SU policy.

By elucidating ways that supported publications are applied outside academia, bibliometrics offer a useful avenue for evaluating the translational impact of programs on specific areas of policy. Our findings showcase the impact that CTSA research has had on SU-related policy literature, a critical area of health policy.

Llewellyn, N. M., Weber, A., Kegley, S., Nehl, E. J., & Abraham, A. J. (2025). From Research Influencers to Substance Use Policymakers: Bibliometrics Demonstrate Translation from Research to Policy. Journal of studies on alcohol and drugs, jsad-25.

Full Article


Cannabis Laws and Opioid Use Among Commercially Insured Patients With Cancer Diagnoses

Pain is a prevalent cancer-associated symptom reported by more than 65% of patients with advanced cancer. 1 Cannabis has shown potential in treating cancer-related pain and alleviating adverse effects from cancer treatments. 2-4 To date, 39 states and Washington, DC, have enacted medical cannabis laws (MCLs) providing cannabis availability for patients with qualifying conditions,
including cancer, while 24 states and Washington, DC, have passed recreational cannabis laws (RCLs) legalizing adult-use cannabis. While opioids remain the recommended treatment for cancer pain, 5, 6 these patients may benefit from cannabis availability for adjuvant therapy. Further, cannabis use may reduce opioid use more among patients with cancer whose pain is not well managed with opioids or who experience negative effects of opioid use.

Although existing literature finds MCLs are associated with improved pain-related outcomes among patients with newly diagnosed cancer,2 no studies examine the effects of RCLs on opioid use among populations with cancer diagnoses or of any cannabis availability on opioid use across subpopulations of patients who may have been traditionally undertreated for pain.7,8 This study fills these gaps by implementing a synthetic control design accounting for variation between populations in states with and without medical cannabis dispensaries (MCDs) and recreational cannabis dispensaries (RCDs).

Lozano-Rojas, F., Bethel, V., Gupta, S., Steuart, S. R., Bradford, W. D., & Abraham, A. J. (2025, October). Cannabis Laws and Opioid Use Among Commercially Insured Patients With Cancer Diagnoses. In JAMA Health Forum (Vol. 6, No. 10, p. e253512). American Medical Association.

Full Article


The Latest News from SPIA

April 2026 MPA Student of the Month: William Gordon

Join us for an Event

Apr 10

MPA Gwinnett Lunch & Learn

12:00 PM - 1:00 PM

Apr 16
Apr 17